In line with these preclinical results, two consecutive phase II and phase III trials showed that the use of this regimen in mCRC patients, elicits a CEA/TS specific T cell response, increases the amount of peripheral and central Tcms, and in parallel decreases the score of tumor infiltrating Tregs [9–11]. This evidence concerns the gene CEACAM5 and neoplasm.